-
81.发明授权公开(公告)号：US08725426B2
公开(公告)日：2014-05-13
申请号：US13752199
申请日：2013-01-28
申请人： Genomic Health, Inc.
发明人： Steve Shak , Mark Lee , William Novotny , Tara Maddala , Michael Crager , Diana Cherbavaz , Robert J. Pelham , Carl L. Millward , Dejan Knezevic
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G06F19/00 , G16H50/30
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
摘要翻译： 本发明提供基于算法的分子测定法，其涉及从前列腺癌患者获得的生物样品中测量基因或其共表达基因的表达水平。 这些基因可以分组成功能性基因子集，用于计算可用于预测前列腺癌患者的临床结果的可能性的定量评分。
-
82.发明申请GENE EXPRESSION MARKERS FOR PREDICTION OF RESPONSE TO PHOSPHOINOSITIDE 3-KINASE INHIBITORS 审中-公开用于预测磷酸三磷酸激酶抑制剂的基因表达标记公开(公告)号：US20130274127A1
公开(公告)日：2013-10-17
申请号：US13804351
申请日：2013-03-14
申请人： GENOMIC HEALTH, INC.
发明人： Joffre B. Baker , Robert J. Pelham , Kevin A. Kwei
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57484 , G01N2800/52
摘要： The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.
摘要翻译： 本发明提供了用于预测肿瘤细胞对磷酸肌醇3-激酶（PI3K）抑制剂敏感或抗性的可能性的方法。 所述方法通常涉及确定与PI3K抑制剂的敏感性或抗性相关的基因产物的表达水平。 本发明还提供了通过使肿瘤细胞与PI3K抑制剂的敏感性或抗性相关的基因产物的活化剂或抑制剂接触来提高肿瘤细胞对PI3K抑制剂的敏感性的方法。
-
83.发明申请公开(公告)号：US20130196321A1
公开(公告)日：2013-08-01
申请号：US13752199
申请日：2013-01-28
申请人： GENOMIC HEALTH, INC.
发明人： Steve Shak , Mark Lee , William Novotny , Tara Maddala , Michael Crager , Diana Cherbavaz , Robert J. Pelham , Carl L. Millward , Dejan Knezevic
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G06F19/00 , G16H50/30
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
摘要翻译： 本发明提供基于算法的分子测定法，其涉及从前列腺癌患者获得的生物样品中测量基因或其共表达基因的表达水平。 这些基因可以分组成功能性基因子集，用于计算可用于预测前列腺癌患者的临床结果的可能性的定量评分。
-
公开(公告)号：US20130102492A1
公开(公告)日：2013-04-25
申请号：US13729462
申请日：2012-12-28
发明人： Wayne Cowens , Joffre B. Baker , Kim Clark-Langone , James Hackett , Drew Watson , Soonmyung Paik
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G01N33/57419 , G01N33/57446
摘要： A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
摘要翻译： 一种预测患有结肠直肠癌的受试者的临床结果的方法，包括确定从受试者获得的癌细胞的生物样品中一种或多种预测性RNA转录物或其表达产物的表达的证据。
-
85.发明授权公开(公告)号：US08273534B2
公开(公告)日：2012-09-25
申请号：US12465503
申请日：2009-05-13
申请人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
发明人： Joffre B. Baker , Drew Watson , Tara Maddala , Steven Shak , David J. Mauro , Shirin K. Ford
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
摘要翻译： 本发明提供了有助于确定个体中EGFR表达的EGFR是否是EGFR抑制剂反应性癌症的方法和组合物，以及用于确定具有EGFR表达癌症的患者的可能性将表现出对 EGFR抑制剂治疗。 所述方法通常涉及确定与EGFR抑制剂反应性相关的基因产物的归一化表达水平。
-
公开(公告)号：US08198024B2
公开(公告)日：2012-06-12
申请号：US13009733
申请日：2011-01-19
申请人： Drew Watson , Soonmyung Paik , Wayne Cowens , Joffre B. Baker , Kim Clark , James Hackett
发明人： Drew Watson , Soonmyung Paik , Wayne Cowens , Joffre B. Baker , Kim Clark , James Hackett
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G01N33/57419 , G01N33/57446
摘要： A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
-
公开(公告)号：US08153378B2
公开(公告)日：2012-04-10
申请号：US12696934
申请日：2010-01-29
申请人： Wayne Cowens , Joffre B. Baker , Kim Clark , James Hackett , Drew Watson , Soonmyung Paik
发明人： Wayne Cowens , Joffre B. Baker , Kim Clark , James Hackett , Drew Watson , Soonmyung Paik
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G01N33/57419 , G01N33/57446
摘要： A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
摘要翻译： 一种预测患有结肠直肠癌的受试者的临床结果的方法，包括确定从受试者获得的癌细胞的生物样品中一种或多种预测性RNA转录物或其表达产物的表达的证据。
-
公开(公告)号：US08071286B2
公开(公告)日：2011-12-06
申请号：US11450964
申请日：2006-06-09
CPC分类号： G01N33/57484 , C12N15/1003 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57415
摘要： The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
摘要翻译： 本发明涉及测量活检肿瘤组织中的mRNA水平的敏感方法，包括归档石蜡包埋的活检材料。 本发明还涉及在乳腺癌诊断和治疗中重要的乳腺癌基因集，以及基于从基因表达研究获得的知识为乳腺癌患者分配最佳治疗选择的方法。
-
公开(公告)号：US08008003B2
公开(公告)日：2011-08-30
申请号：US10714195
申请日：2003-11-14
申请人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
发明人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16
摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。
-
公开(公告)号：US07939261B2
公开(公告)日：2011-05-10
申请号：US12406831
申请日：2009-03-18
申请人： Joffre B. Baker , John L. Bryant , Soonmyung Paik , Steven Shak
发明人： Joffre B. Baker , John L. Bryant , Soonmyung Paik , Steven Shak
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57415 , G01N33/57484 , G01N33/57492 , G06F19/20 , G06F19/24
摘要： The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
摘要翻译： 本发明提供了癌症患者预后测定的无创定量试验。 测试依赖于某些信使RNA（mRNA）的肿瘤水平的测量。 将这些mRNA水平插入到产生数字复发评分的多项式公式（算法）中，其表示复发风险。
-
-
-
-
-
-
-
-
-
搜索结果
93 条记录 (耗时 0.064 秒)
